AU2002223968A1 - Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists - Google Patents

Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists

Info

Publication number
AU2002223968A1
AU2002223968A1 AU2002223968A AU2396802A AU2002223968A1 AU 2002223968 A1 AU2002223968 A1 AU 2002223968A1 AU 2002223968 A AU2002223968 A AU 2002223968A AU 2396802 A AU2396802 A AU 2396802A AU 2002223968 A1 AU2002223968 A1 AU 2002223968A1
Authority
AU
Australia
Prior art keywords
methyl
piperidine derivatives
subtype selective
aspartate antagonists
aspartate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002223968A
Other languages
English (en)
Inventor
Brian Edward Kornberg
Russell Andrew Lewthwaite
David Douglas Manning
Sham Shridhar Nikam
Ian Leslie Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of AU2002223968A1 publication Critical patent/AU2002223968A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002223968A 2000-12-21 2001-11-30 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists Abandoned AU2002223968A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25783200P 2000-12-21 2000-12-21
US60/257,832 2000-12-21
PCT/IB2001/002277 WO2002050070A2 (en) 2000-12-21 2001-11-30 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists

Publications (1)

Publication Number Publication Date
AU2002223968A1 true AU2002223968A1 (en) 2002-07-01

Family

ID=22977943

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002223968A Abandoned AU2002223968A1 (en) 2000-12-21 2001-11-30 Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists

Country Status (13)

Country Link
US (1) US6642256B2 (zh)
EP (1) EP1345935A2 (zh)
JP (1) JP2004516295A (zh)
AU (1) AU2002223968A1 (zh)
BR (1) BR0116311A (zh)
CA (1) CA2436699A1 (zh)
HN (1) HN2001000280A (zh)
MX (1) MXPA03004652A (zh)
PA (1) PA8535901A1 (zh)
PE (1) PE20020882A1 (zh)
TN (1) TNSN01175A1 (zh)
UY (1) UY27081A1 (zh)
WO (1) WO2002050070A2 (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) * 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW200303304A (en) 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
EP1663999A2 (en) * 2003-08-29 2006-06-07 Ranbaxy Laboratories, Ltd. Inhibitors of phosphodiesterase type-iv
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
GT200600042A (es) * 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
JPWO2006137465A1 (ja) * 2005-06-24 2009-01-22 塩野義製薬株式会社 含窒素複素環誘導体
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
AU2008224541B2 (en) 2007-03-14 2013-08-22 Sun Pharmaceutical Industries Limited Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
JP5573307B2 (ja) * 2010-03-31 2014-08-20 Ｊｓｒ株式会社 感放射線性樹脂組成物、重合体及び化合物
CA2802295C (en) 2010-06-11 2016-09-20 Rhodes Technologies Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof
EP2592077A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
CA3033827A1 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
WO2018169818A1 (en) * 2017-03-12 2018-09-20 Xiaodong Wang Polycyclic amines as opioid receptor modulators
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2205998C (en) * 1994-11-23 2002-07-16 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
DE19531321A1 (de) 1995-08-25 1997-02-27 Merck Patent Gmbh Piperidinylmethyloxazolidinone
ZA9610745B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
DE19739332C1 (de) 1997-09-09 1998-11-26 Merck Patent Gmbh Piperidinylmethyloxazolidinon-Derivat
US6015824A (en) 1998-02-10 2000-01-18 Hoffmann-La Roche Ag Pyrrolidine and piperidine derivatives and treatment of neurodegenerative disorders
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
WO1999050264A1 (fr) 1998-03-30 1999-10-07 Kyowa Hakko Kogyo Co., Ltd. Derives de quinazoline
WO2000018763A2 (en) 1998-09-29 2000-04-06 Neurogen Corporation 2-(2,3-dihydrobenzofuran-5-yl)-4-aminomethylimidazoles: dopamine receptor subtype specific ligands

Also Published As

Publication number Publication date
PE20020882A1 (es) 2002-09-28
EP1345935A2 (en) 2003-09-24
UY27081A1 (es) 2002-07-31
HN2001000280A (es) 2002-01-30
MXPA03004652A (es) 2003-09-05
JP2004516295A (ja) 2004-06-03
WO2002050070A3 (en) 2002-09-19
TNSN01175A1 (fr) 2005-11-10
BR0116311A (pt) 2003-09-23
PA8535901A1 (es) 2002-08-29
WO2002050070A2 (en) 2002-06-27
CA2436699A1 (en) 2002-06-27
US20030018021A1 (en) 2003-01-23
US6642256B2 (en) 2003-11-04

Similar Documents

Publication Publication Date Title
AU2002210782A1 (en) Amide derivatives as nmda receptor antagonists
ZA200108867B (en) Piperidine derivatives useful as CCR5 antagonists.
AU2001255798A1 (en) Glucagon antagonists
AU2002216028A1 (en) Novel carbamate-substituted pyrazolopyridine derivatives
AU2002221827A1 (en) Novel lactame-substituted pyrazolopyridine derivatives
IL145741A0 (en) Piperazine derivatives useful as ccrs antagonists
IL152209A0 (en) Benzoamide piperidine compounds as substance p antagonists
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2002227919A1 (en) Novel sulfonamide-substituted pyrazolopyridine derivatives
AU2002223968A1 (en) Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists
AU2002224038A1 (en) Benzimidazole derivatives
IL160060A0 (en) Piperidine derivatives useful as ccr5 antagonists
AU2001242744A1 (en) Diphenylalkylamine derivatives useful as opioid delta receptor ligands
PL358584A1 (en) Cyclohexylamine derivative as subtype selective nmda receptor antagonists
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2001261487A1 (en) Cyclohexylamine derivatives as subtype selective nmda receptor antagonists
AU2001231664A1 (en) Indol-3-yl derivatives
SI1368299T1 (sl) Substituirani C-cikloheksilmetilaminski derivati
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
AU2001295455A1 (en) Indoline derivatives as 5ht2c antagonists
HK1052925B (zh) 取代的1-氨基丁-3-醇衍生物